US4910215A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical formulations designed to stimulate the release of somatotropic hormone
Assignee: Individual
•
Filing: 1988-04-12
•
Granted: 1990-03-20
•
Expires: 2008-04-12
Abstract
Abstract The use of 2,6-dichlorophenyl compounds as active principles in pharmaceutical formulations designed to stimulate the secretion or release of somatotropic hormone in man and animals is described.
Inventors
- 👤 Eugenio Muller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 08:55
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
37 words
A method for treating a child with impaired growth caused by hypothalamic abnormality, which comprises administering to such child therapeutically effective amounts of clonidine for a period of at least two months, so as to induce growth.
Claim 2
Independent Claim
37 words
A method for treating a child with impaired growth caused by hypothalamic abnormality, which comprises administering to such child therapeutically effective amounts of clonidine for a period of at least two months, so as to induce growth.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the child to be treated suffers from isolated growth hormone deficiency.
Claim 4
Dependent Claim
16 words
The method of claim 1 wherein the child to be treated suffers from constitutional growth delay.
Claim 5
Dependent Claim
28 words
The method of claim 1 wherein about 0.1 mg/m 2 (of body surface) of clonidine is administered orally, daily, for a period of at least about two months.
Claim 6
Independent Claim
43 words
A method for treating a child suffering from impaired growth due to hypothalamic abnormality which comprises orally administering about 0.1 mg/m 2 (of body surface) of clonidine per day for a period of at least about two months so as to induce growth.
Claim 7
Independent Claim
43 words
A method for treating a child suffering from impaired growth due to hypothalamic abnormality which comprises orally administering about 0.1 mg/m 2 (of body surface) of clonidine per day for a period of at least about two months so as to induce growth.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-19 | 1993-09-18 | 1994-03-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-19 | 1997-09-18 | 1998-03-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-19 | 2001-09-18 | 2002-03-20 | $7700.00 | Window Closed / Lapsed |